Literature DB >> 18625133

Management of high-grade dysplasia.

Francesco Palazzo1, Piero M Fisichella, Marco G Patti.   

Abstract

High-grade dysplasia is the last stage before the development of adenocarcinoma. Despite the fact that the lesion is not yet invasive, it has tremendous potential to become malignant. The approach to the disease has clinicians divided between immediate intervention with surgical resection or continued endoscopic surveillance proof of the unclear natural history. Much knowledge has been acquired recently regarding application of surveillance and outcomes of esophageal resection. Also, many endoscopic techniques for treating high-grade dysplasia have been studied in depth. Results on their safety, efficacy, and complication rates have recently become available. This review analyzes the progress in the understanding and treatment of high-grade dysplasia during the past 24 to 36 months and examines how this new information plays a role in the disease's treatment algorithm.

Entities:  

Mesh:

Year:  2008        PMID: 18625133     DOI: 10.1007/s11894-008-0050-7

Source DB:  PubMed          Journal:  Curr Gastroenterol Rep        ISSN: 1522-8037


  43 in total

1.  Effect of operative volume on morbidity, mortality, and hospital use after esophagectomy for cancer.

Authors:  S G Swisher; L Deford; K W Merriman; G L Walsh; R Smythe; A Vaporicyan; J A Ajani; T Brown; R Komaki; J A Roth; J B Putnam
Journal:  J Thorac Cardiovasc Surg       Date:  2000-06       Impact factor: 5.209

Review 2.  The diagnosis of dysplasia and malignancy in Barrett's oesophagus.

Authors:  K Geboes; P Van Eyken
Journal:  Histopathology       Date:  2000-08       Impact factor: 5.087

3.  Updated guidelines for the diagnosis, surveillance, and therapy of Barrett's esophagus.

Authors:  Richard E Sampliner
Journal:  Am J Gastroenterol       Date:  2002-08       Impact factor: 10.864

4.  Outcomes after esophagectomy: a ten-year prospective cohort.

Authors:  Stephen H Bailey; David A Bull; David H Harpole; Jeffrey J Rentz; Leigh A Neumayer; Theodore N Pappas; Jennifer Daley; William G Henderson; Barbara Krasnicka; Shukri F Khuri
Journal:  Ann Thorac Surg       Date:  2003-01       Impact factor: 4.330

Review 5.  Postoperative mortality following oesophagectomy and problems in reporting its rate.

Authors:  G G Jamieson; G Mathew; R Ludemann; J Wayman; J C Myers; P G Devitt
Journal:  Br J Surg       Date:  2004-08       Impact factor: 6.939

6.  Early experience with radiofrequency energy ablation therapy for Barrett's esophagus with and without dysplasia.

Authors:  A K Roorda; S N Marcus; G Triadafilopoulos
Journal:  Dis Esophagus       Date:  2007       Impact factor: 3.429

7.  An inverse relation between cagA+ strains of Helicobacter pylori infection and risk of esophageal and gastric cardia adenocarcinoma.

Authors:  W H Chow; M J Blaser; W J Blot; M D Gammon; T L Vaughan; H A Risch; G I Perez-Perez; J B Schoenberg; J L Stanford; H Rotterdam; A B West; J F Fraumeni
Journal:  Cancer Res       Date:  1998-02-15       Impact factor: 12.701

8.  Comparison of the outcomes between open and minimally invasive esophagectomy.

Authors:  Bernard M Smithers; David C Gotley; Ian Martin; Janine M Thomas
Journal:  Ann Surg       Date:  2007-02       Impact factor: 12.969

Review 9.  Endoscopic mucosal resection of Barrett's oesophagus containing dysplasia or intramucosal cancer.

Authors:  S Seewald; T L Ang; N Soehendra
Journal:  Postgrad Med J       Date:  2007-06       Impact factor: 2.401

10.  Esophagectomy for high grade dysplasia is safe, curative, and results in good alimentary outcome.

Authors:  Valerie A Williams; Thomas J Watson; Fernando A Herbella; Oliver Gellersen; Daniel Raymond; Carolyn Jones; Jeffrey H Peters
Journal:  J Gastrointest Surg       Date:  2007-10-02       Impact factor: 3.452

View more
  1 in total

Review 1.  Mucosal ablation of Barrett esophagus.

Authors:  Irving Waxman; Vani J A Konda
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2009-06-02       Impact factor: 46.802

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.